If you are a big pharmaceutical company, spending millions of dollars to manage your intellectual property every year, you will want to find the best lawyers to advise you on prosecution and litigation matters. But as Susanne Sivborg, vice-president of global intellectual property at AstraZeneca, tells Stéphanie Bodoni, the most experienced lawyers are no good if they do not respond to her company's needs
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Rebekah Gay discusses overcoming self-doubt, supporting the next generation of women lawyers, and how changing client demands are reshaping IP practice
New filing data suggests Germany's grip on UPC litigation remains strong, while Bardehle Pagenberg, Arnold Ruess, Hogan Lovells and Carpmaels notch up notable cases
Cindy Goh discusses why she launched Cheang & Ariff's IP department, the improving litigation environment in Malaysia and what to consider when using AI
IPH's Canadian acquisitions are paying off on paper, but a couple of strong years may not be enough to show that the group's strategy has truly won over the market
Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators